孟鲁司特联合沙美特罗替卡松治疗咳嗽变异性哮喘疗效观察

目的: 探讨孟鲁司特联合沙美特罗替卡松在治疗咳嗽变异性哮喘(CVA)中的疗效。方法: 将40例CVA患者随机分为治疗组和对照组各20例。对照组采用丙卡特罗25 μg口服,每天2次;氨茶碱0.1 g口服,每天3次。治疗组20例采用沙美特罗替卡松50 μg/250 μg吸入,每天2次;孟鲁司特10 mg口服,每天1次。总疗程4周。观察治疗4周后患者咳嗽好转情况及第1秒用力呼气量(FEV1)和FEV1%的变化。结果: 治疗组疗效明显好于对照组(P<0.01),有效率达90%。2组肺功能FEV1和FEV1%均较治疗前明显改善(P<0.01),但治疗组较对照组改善更明显(P<0.01)。结论: 孟鲁司特与沙美特罗替卡松联合应用可明显改善CVA的咳嗽症状及肺功能,疗效优于传统的支气管舒张剂及止咳药物。

Treatment effect of Montelukast combined with Seretide on cough variant asthma

Objective: To explore the effects of Montelukast combined with Seretide in the treatment of cough variant asthma(CVA).Methods: Forty patients with CVA were randomly divided into the treatment group and control group(20 cases each group).The control group were treated with 25 μg of procaterol twice a day,0.1g of aminophylline 3 times a day by oral.The treatment group were treated with 50 μg/250 μg of Seretide twice a day by inhalation combined with 10 mg of Montelukast once a day by oral.The cough improvement,forced expiratory volume 1 second(FEV1) and FEV1% in all cases were observed during the 4 weeks treatment.Results: The effects of the treatment group were significantly better than that of the control group at 4 weeks after treatment(P<0.01),the disappearance rate of cough in treatment group was 90%.Compared with before treatment,the FEV1 and FEV1% in two groups were significantly improved at 4 weeks after treatment(P<0.01),especially for the treatment group(P<0.01).Conclusions: The treatment with Montelukast,combined with Seretide can significantly improve the cough symptoms and lung function of patients with CVA,the effects of which are better than the bronchodilation agents and relieving cough and reducing sputum drugs.